271 related articles for article (PubMed ID: 14871543)
1. Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
Kukreja RC; Ockaili R; Salloum F; Yin C; Hawkins J; Das A; Xi L
J Mol Cell Cardiol; 2004 Feb; 36(2):165-73. PubMed ID: 14871543
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications.
Kukreja RC; Salloum F; Das A; Ockaili R; Yin C; Bremer YA; Fisher PW; Wittkamp M; Hawkins J; Chou E; Kukreja AK; Wang X; Marwaha VR; Xi L
Vascul Pharmacol; 2005; 42(5-6):219-32. PubMed ID: 15922255
[TBL] [Abstract][Full Text] [Related]
3. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
Gresser U; Gleiter CH
Eur J Med Res; 2002 Oct; 7(10):435-46. PubMed ID: 12435622
[TBL] [Abstract][Full Text] [Related]
4. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].
Chen Q; Wang N; Yao F; Lu X
Zhonghua Nan Ke Xue; 2004 Apr; 10(4):302-4. PubMed ID: 15148932
[TBL] [Abstract][Full Text] [Related]
6. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides.
Steiner MK; Preston IR; Klinger JR; Hill NS
Curr Opin Pharmacol; 2005 Jun; 5(3):245-50. PubMed ID: 15907910
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 5 inhibitors for erectile dysfunction.
Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
[TBL] [Abstract][Full Text] [Related]
10. Sildenafil: emerging cardiovascular indications.
Raja SG; Nayak SH
Ann Thorac Surg; 2004 Oct; 78(4):1496-506. PubMed ID: 15464535
[TBL] [Abstract][Full Text] [Related]
11. Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy.
Rondelet B; Kerbaul F; Van Beneden R; Motte S; Fesler P; Hubloue I; Remmelink M; Brimioulle S; Salmon I; Ketelslegers JM; Naeije R
Circulation; 2004 Oct; 110(15):2220-5. PubMed ID: 15466636
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit.
Firoozi F; Longhurst PA; White MD
BJU Int; 2005 Jul; 96(1):164-8. PubMed ID: 15963142
[TBL] [Abstract][Full Text] [Related]
13. Sildenafil extends survival and graft function in a large animal lung transplantation model.
Korom S; Hillinger S; Cardell M; Zhai W; Tan Q; Dutly A; Leskosek B; Weder W
Eur J Cardiothorac Surg; 2006 Mar; 29(3):288-93. PubMed ID: 16442298
[TBL] [Abstract][Full Text] [Related]
14. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
Patel MD; Katz SD
Am J Cardiol; 2005 Dec; 96(12B):47M-51M. PubMed ID: 16387567
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
Ghofrani HA; Grimminger F
Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S311-4. PubMed ID: 17139594
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects.
Werkström V; Svensson A; Andersson KE; Hedlund P
BJU Int; 2006 Aug; 98(2):414-23. PubMed ID: 16626307
[TBL] [Abstract][Full Text] [Related]
18. [Levitra (vardenafil)--a new PDE 5 inhibitor for the treatment of erectile dysfunction].
Katsarov M
Akush Ginekol (Sofiia); 2004; 43 Suppl 1():31-2. PubMed ID: 15323315
[No Abstract] [Full Text] [Related]
19. [7 years PDE-5 inhibitor for therapy of erection disorders].
Krankenpfl J; 2005; 43(7-10):267. PubMed ID: 16518894
[No Abstract] [Full Text] [Related]
20. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
Wharton J; Strange JW; Møller GM; Growcott EJ; Ren X; Franklyn AP; Phillips SC; Wilkins MR
Am J Respir Crit Care Med; 2005 Jul; 172(1):105-13. PubMed ID: 15817798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
